Hikma Pharmaceuticals upgrades 2013 revenue outlook

Shares in Hikma Pharmaceuticals rose Thursday after the company upgraded its 2013 revenue growth forecast following a "strong start to the year".

Shares in Hikma Pharmaceuticals rose Thursday after the company upgraded its 2013 revenue growth forecast following a "strong start to the year".

The group expects revenue to rise 13% this year, up from its previous guidance of 10%, driven by the performance of Branded and Injectables and Generics businesses in the year-to-date.

The Branded and Injectables unit is on track to meet the firm's full-year guidance while the Generics arm is continuing to benefit from its doxycycline product which is delivering revenue ahead of forecasts.

"We have made a very good start to 2013 across all of our businesses and I am pleased to be able to raise our group guidance for the full year," said Chief Executive Officer Said Darwazah.

The company's branded business was boosted by the introduction of new products and enhancements in sales and marketing activities. The unit has experienced improvement in markets including Algeria, Egypt and Saudi Arabia.

In January, Hikma completed the acquisition of the Egyptian Company for Pharmaceuticals and Chemical Industries which has since been fully integrated.

Branded revenue is expected to increase 11% in 2013, with a slight improvement in adjusted operating margin.

The Injectables division has been performing well in the US, supported by new product launches, price improvements and our continued focus on operational efficiencies.

Full-year guidance for the Generics business is for revenue of $150m and operating margin in the low teens.

"Overall, our diversified business model is positioning the group to deliver another strong year in 2013," Arabia said.

Shares climbed 2.32% to 1,014p at 12:43 Thursday.

RD

Recommended

The MoneyWeek Podcast: picking stocks is fun, but you need to do your homework
Investment strategy

The MoneyWeek Podcast: picking stocks is fun, but you need to do your homework

John Stepek talks to Steve Clapham, investor, analyst and author of The Smart Money Method, about the dangers in picking individual stocks and why you…
8 Apr 2021
BP looks set to return more money to shareholders as it beats expectations
Energy stocks

BP looks set to return more money to shareholders as it beats expectations

Oil major BP is to embark on a share buyback programme after significantly reducing its debts. Saloni Sardana looks at what it means for your portfoli…
6 Apr 2021
Deliveroo has hit the market – but it’s not getting the warmest welcome
UK stockmarkets

Deliveroo has hit the market – but it’s not getting the warmest welcome

Food delivery company Deliveroo made its debut on the stockmarket this morning. But with the share price sliding by 30% straight away, it’s not made t…
31 Mar 2021
Three stocks to buy now that will come back stronger after Covid-19
Share tips

Three stocks to buy now that will come back stronger after Covid-19

Professional investor Ed Wielechowski of Odyssean Capital, chooses three compelling stocks that should thrive in a post-pandemic world.
29 Mar 2021

Most Popular

The bitcoin bubble will burst: here’s how to play it
Bitcoin

The bitcoin bubble will burst: here’s how to play it

The cryptocurrency’s price has soared far beyond its fundamentals, says Matthew Partridge. Here, he looks at how to short bitcoin.
12 Apr 2021
What does the Coinbase listing mean for bitcoin and other cryptocurrencies?
Bitcoin

What does the Coinbase listing mean for bitcoin and other cryptocurrencies?

As the bitcoin price hit new highs, the world's biggest cryptocurrency exchange, Coinbase, listed on the stockmarket. John Stepek looks at what that m…
15 Apr 2021
Lab-grown meat: the new agricultural revolution
Soft commodities

Lab-grown meat: the new agricultural revolution

Vegan alternatives are taking off, but the future of food technology lies in lab-grown meat – cultivating steaks and burgers from animal cells, says A…
16 Apr 2021